vs
ANI PHARMACEUTICALS INC（ANIP）とRanger Energy Services, Inc.（RNGR）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $142.2M、Ranger Energy Services, Inc.の約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 2.3%、差は8.9%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -0.6%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $17.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 1.9%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
レンジャー・エナジー・サービシズ社は北米屈指の陸上油田サービスプロバイダーであり、上流の石油・ガス事業者に対して坑井完成、修井、リグ運用、生産性向上ソリューションを提供し、主に米国本土のシェール・緻密資源開発地域で事業を展開しています。
ANIP vs RNGR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $142.2M |
| 純利益 | $27.5M | $3.2M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 2.3% |
| 純利益率 | 11.1% | 2.3% |
| 売上前年比 | 29.6% | -0.6% |
| 純利益前年比 | 367.5% | -44.8% |
| EPS（希薄化後） | $1.14 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $142.2M | ||
| Q3 25 | $227.8M | $128.9M | ||
| Q2 25 | $211.4M | $140.6M | ||
| Q1 25 | $197.1M | $135.2M | ||
| Q4 24 | $190.6M | $143.1M | ||
| Q3 24 | $148.3M | $153.0M | ||
| Q2 24 | $138.0M | $138.1M | ||
| Q1 24 | $137.4M | $136.9M |
| Q4 25 | $27.5M | $3.2M | ||
| Q3 25 | $26.6M | $1.2M | ||
| Q2 25 | $8.5M | $7.3M | ||
| Q1 25 | $15.7M | $600.0K | ||
| Q4 24 | $-10.3M | $5.8M | ||
| Q3 24 | $-24.2M | $8.7M | ||
| Q2 24 | $-2.3M | $4.7M | ||
| Q1 24 | $18.2M | $-800.0K |
| Q4 25 | 14.1% | 2.3% | ||
| Q3 25 | 15.9% | 2.0% | ||
| Q2 25 | 6.6% | 6.1% | ||
| Q1 25 | 13.3% | 0.7% | ||
| Q4 24 | -2.3% | 6.2% | ||
| Q3 24 | -13.8% | 8.4% | ||
| Q2 24 | 3.7% | 5.3% | ||
| Q1 24 | 14.8% | -0.4% |
| Q4 25 | 11.1% | 2.3% | ||
| Q3 25 | 11.7% | 0.9% | ||
| Q2 25 | 4.0% | 5.2% | ||
| Q1 25 | 8.0% | 0.4% | ||
| Q4 24 | -5.4% | 4.1% | ||
| Q3 24 | -16.3% | 5.7% | ||
| Q2 24 | -1.7% | 3.4% | ||
| Q1 24 | 13.2% | -0.6% |
| Q4 25 | $1.14 | $0.14 | ||
| Q3 25 | $1.13 | $0.05 | ||
| Q2 25 | $0.36 | $0.32 | ||
| Q1 25 | $0.69 | $0.03 | ||
| Q4 24 | $-0.45 | $0.24 | ||
| Q3 24 | $-1.27 | $0.39 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $-0.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $10.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $300.1M |
| 総資産 | $1.4B | $419.3M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $10.3M | ||
| Q3 25 | $262.6M | $45.2M | ||
| Q2 25 | $217.8M | $48.9M | ||
| Q1 25 | $149.8M | $40.3M | ||
| Q4 24 | $144.9M | $40.9M | ||
| Q3 24 | $145.0M | $14.8M | ||
| Q2 24 | $240.1M | $8.7M | ||
| Q1 24 | $228.6M | $11.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $540.7M | $300.1M | ||
| Q3 25 | $505.8M | $270.0M | ||
| Q2 25 | $436.8M | $276.9M | ||
| Q1 25 | $418.6M | $272.6M | ||
| Q4 24 | $403.7M | $273.8M | ||
| Q3 24 | $405.9M | $267.6M | ||
| Q2 24 | $455.8M | $260.5M | ||
| Q1 24 | $452.0M | $261.7M |
| Q4 25 | $1.4B | $419.3M | ||
| Q3 25 | $1.4B | $372.8M | ||
| Q2 25 | $1.3B | $381.7M | ||
| Q1 25 | $1.3B | $376.5M | ||
| Q4 24 | $1.3B | $381.6M | ||
| Q3 24 | $1.3B | $373.9M | ||
| Q2 24 | $920.8M | $359.6M | ||
| Q1 24 | $914.5M | $355.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $24.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $17.1M |
| FCFマージンFCF / 売上 | 11.8% | 12.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 7.53× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $42.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $24.1M | ||
| Q3 25 | $44.1M | $13.6M | ||
| Q2 25 | $75.8M | $20.7M | ||
| Q1 25 | $35.0M | $10.6M | ||
| Q4 24 | $15.9M | $32.7M | ||
| Q3 24 | $12.5M | $17.7M | ||
| Q2 24 | $17.4M | $22.1M | ||
| Q1 24 | $18.3M | $12.0M |
| Q4 25 | $29.1M | $17.1M | ||
| Q3 25 | $38.0M | $8.0M | ||
| Q2 25 | $71.8M | $14.4M | ||
| Q1 25 | $32.5M | $3.4M | ||
| Q4 24 | $13.5M | $27.3M | ||
| Q3 24 | $7.7M | $10.8M | ||
| Q2 24 | $13.0M | $6.8M | ||
| Q1 24 | $13.7M | $5.5M |
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 16.7% | 6.2% | ||
| Q2 25 | 34.0% | 10.2% | ||
| Q1 25 | 16.5% | 2.5% | ||
| Q4 24 | 7.1% | 19.1% | ||
| Q3 24 | 5.2% | 7.1% | ||
| Q2 24 | 9.4% | 4.9% | ||
| Q1 24 | 10.0% | 4.0% |
| Q4 25 | 0.5% | 4.9% | ||
| Q3 25 | 2.7% | 4.3% | ||
| Q2 25 | 1.9% | 4.5% | ||
| Q1 25 | 1.3% | 5.3% | ||
| Q4 24 | 1.3% | 3.8% | ||
| Q3 24 | 3.2% | 4.5% | ||
| Q2 24 | 3.2% | 11.1% | ||
| Q1 24 | 3.3% | 4.7% |
| Q4 25 | 1.10× | 7.53× | ||
| Q3 25 | 1.66× | 11.33× | ||
| Q2 25 | 8.87× | 2.84× | ||
| Q1 25 | 2.23× | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 4.70× | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
